Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12608047 | 0.87 | DRD2 (0.51) | DRD2DRD1DRD5DRD3HRH3 | |
| SCHEMBL12565723 | 0.86 | DRD2 (0.53) | DRD2DRD1DRD5DRD3HRH3 | |
| SCHEMBL1132759 | 0.83 | DRD2 (0.54) | DRD2DRD1DRD5DRD3HRH3 | |
| SCHEMBL13255040 | 0.82 | HRH3 (0.57) | DRD2DRD1DRD5DRD3HRH3 | |
| SCHEMBL3247682 | 0.81 | DRD2 (0.51) | DRD2DRD1DRD5DRD3HRH3 | |
| SCHEMBL8496974 | 0.80 | KCNH2 (0.54) | DRD2DRD1DRD5DRD3ABCB1 | |
| SCHEMBL8506549 | 0.79 | DRD2 (0.49) | DRD2DRD1DRD5DRD3HRH3 | |
| SCHEMBL12608592 | 0.79 | DRD2 (0.53) | DRD2DRD1DRD5DRD3HRH3 | |
| SCHEMBL5456113 | 0.78 | DRD2 (0.44) | DRD2DRD1DRD5DRD3PRMT5 | |
| SCHEMBL5458468 | 0.78 | DRD2 (0.44) | DRD2DRD1DRD5DRD3PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299035-B2 | 10a-azalide compound having 4-membered ring structure | TAISHO PHARMACEUTUCAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2287173-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | ELOVL3, ELOVL5, SCD5 | DRD2 375/4885DRD1 472/4885DRD5 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.